Table 1.
Patient and treatment characteristics.
| Variables | No. (%) |
|---|---|
| Age at diagnosis, y | |
| Mean (SD) | 51.9 (8.5) |
| Median (IQR) | 53.5 (44.3-59.3) |
| Histology | |
| Squamous cell carcinoma | 15 (83.3) |
| Adenocarcinoma | 3 (16.7) |
| FIGO staging | |
| IIB | 8 (44.4) |
| IIIA | 1 (5.6) |
| IIIB | 8 (44.4) |
| IVA | 1 (5.6) |
| Parametrial score | |
| 3 or less | 9 (50) |
| More than 3 | 9 (50) |
| Hydroureteronephrosis | |
| Present | 5 (27.8) |
| Absent | 13 (72.2) |
| Pelvic nodes | |
| Present | 11 (61.1) |
| Absent | 7 (38.9) |
| External beam radiotherapy | |
| 50.4 Gy in 28 fractions (1.8 Gy/fraction) | 16 (88.9) |
| 50 Gy in 18 fractions (2.78 Gy/fraction) | 2 (11.1) |
| Intracavitary brachytherapy | |
| 3 Fractions of 7 Gy each weekly | 18 (100) |
| Concurrent chemotherapy | |
| Weekly cisplatin 40 mg/m2 | 14 (77.8) |
| Weekly carboplatin (AUC 6) | 1 (5.6) |
| None | 3 (16.7) |
| Overall treatment time | |
| <9 wk | 11 (61.1) |
| 9 wk or more | 7 (38.9) |
| Minimum haemoglobin level during treatment | |
| <10 g/dL | 6 (33.3) |
| 10 g/dL or more | 11 (61.1) |
| Missing data | 1 (5.6) |
| Follow-up status | |
| Alive without disease | 11 (61.1) |
| Alive with disease | 2 (11.1) |
| Dead | 5 (27.8) |
Abbreviations: FIGO, Federation of Obstetrics and Gynaecology; IQR, interquartile range.